NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
According to the brokerage firm Anand Rathi, FY27 is shaping up as an inflection year for Jubilant Ingrevia Ltd. with contract development manufacturing organisation ramp-up, improving nutrition mix and operating leverage across newly commissioned assets.
At -1SD valuation (~13-14x EV/Ebitda vs implied 17.5x FY28e EV/Ebitda on its target price), the stock remains underpriced despite emerging CDMO visibility and specialty mix upgradation.
Anand Rathi has maintained its Buy rating with unchanged SOTP-based target price of Rs 975.
Key Risks:
- Execution risk in CDMO; and
- Slower ramp-up of human-grade B3 capacity utilisation.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
